FierceBiotechOriginal article
{"a":[{"_":"BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout","$":{"href":"/biotech/biontech-sets-survival-standard-hard-treat-cancer-ahead-pivotal-readout","hreflang":"en"}}]}
Data ReadoutpositivegotistobartPositive
AI Analysis
Summary
BioNTech reported that gotistobart (anti-CTLA-4 antibody) achieved a median overall survival of 18.5 months in relapsed lung cancer patients, demonstrating improvement over the standard of care ahead of a pivotal readout.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
gotistobart demonstrated median overall survival of 18.5 months in relapsed lung cancer patients, showing improvement over standard of care
Importance:7/10
Sentiment:
0.70
oncologylung cancerimmunotherapyanti-CTLA-4survival datapivotal trial
Related Companies
Read the original article
Published by FierceBiotech on September 11, 2026 9:30 AM